Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 601–700 of 1,026
Potential pitfalls when interpreting plasma BNP levels in heart failure practice
Nishikimi, T., & Nakagawa, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.05.003 · Cited by 81
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Patel, J., Rassekh, N., Fonarow, G. C., DEEDWANIA, P. C., Sheikh, F. H., Ahmed, A., & Lam, P. H. (2023) · Drugs · doi:10.1007/s40265-023-01887-4 · Cited by 89
Shi, J., Wang, X., Nguyen, J., Wu, A. H., Bleske, B. E., & Zhu, H. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068536 · Cited by 78
“(McMurray et al., 2014).”
BackgroundBavishi, C., Bangalore, S., & Messerli, F. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.10.002 · Cited by 76
Willard, J. R., Barrow, B. M., & Zraika, S. (2016) · Diabetologia · doi:10.1007/s00125-016-4172-4 · Cited by 77
“and their use is well tolerated with no serious adverse events [28], our data argue that further studies are warranted to elucidate the clinical utility of neprilysin inhibitors in type 2 diabetes”
BackgroundSupasyndh, O., Wang, J., Hafeez, K., Zhang, Y., Zhang, J. Y., & Rakugi, H. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx111 · Cited by 76
Kapelios, C. J., Laroche, C., Crespo‐Leiro, M. G., Anker, S. D., Coats, A. J. S., Molina, B. D., Filippatos, G. S., Lainščak, M., Maggioni, A. P., McDonagh, T. A., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1796 · Cited by 69
Jordan, J., Birkenfeld, A. L., Melander, O., & Moro, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11081 · Cited by 68
Challenging Issues in Clinical Trial Design
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.051 · Cited by 77
“001 for both the composite primary endpoint (CV death or hospitalization for heart failure) and CV death alone at its second interim analysis, when two-thirds of primary events had occurred (41).”
BackgroundIncreased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes
Gutta, S., Grobe, N., Kumbaji, M., Osman, H., Saklayen, M. G., Li, G., & Elased, K. M. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00565.2017 · Cited by 75
“In 2014, management of chronic heart failure through NEP inhibition received more attention based on the positive cardiovascular effects seen in the PARADIGM-HF trial, in which NEP inhibition was combined with Ang II type 1 receptor blockade (31).”
BackgroundMazurek, J. A., & Jessup, M. L. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.001 · Cited by 92
Angelis, E. D., Pecoraro, M., Rusciano, M. R., Ciccarelli, M., & Popolo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071698 · Cited by 73
“By simultaneously inhibiting the angiotensin receptor and neprilysin, the sacubitril/valsartan association improves cardiac dysfunction, hypertension, cardiovascular injury, and ischemic brain damage in experimental and clinical studies [113].”
BackgroundGatti, M., Antonazzo, I. C., Diemberger, I., De Ponti, F., & Raschi, E. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915663 · Cited by 68
Saravi, B., Li, Z., Lang, C. N., Schmid, B., Lang, F. K., Grad, S., Alini, M., Richards, R. G., Schmal, H., Südkamp, N. P., et al. (2021) · Cells · doi:10.3390/cells10030650 · Cited by 75
“In the PARADIGM‐HF study, the additional use of sacubitril/valsartan compared to enalapril reduced death and hospitalization in patients with symptomatic heart failure (EF ≤ 40%) [114].”
BackgroundMethodAngiotensin II receptor type 1 – An update on structure, expression and pathology
Eckenstaler, R., Sandori, J., Gekle, M., & Benndorf, R. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114673 · Cited by 74
Design of Major Randomized Trials
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.036 · Cited by 76
“For example, in the PARADIGM-HF trial in heart failure, comparing LCZ696 with enalapril (20), the consequent superiority of LCZ696 is liable to have a far greater impact than if a placebo control had been”
MethodResultCardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk
Sarzani, R., Spannella, F., Giulietti, F., Balietti, P., Cocci, G., & Bordicchia, M. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0196-1 · Cited by 79
Management of Heart Failure in Advancing CKD: Core Curriculum 2018
House, A. A. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.006 · Cited by 69
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Esser, N., & Zraika, S. (2019) · Diabetologia · doi:10.1007/s00125-019-4889-y · Cited by 75
Baliga, R. S., Preedy, M. E. J., Dukinfield, M., Chu, S. M., Aubdool, A. A., Bubb, K. J., Moyes, A. J., Tones, M. A., & Hobbs, A. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800996115 · Cited by 67
Senni, M., Wachter, R., Witte, K. K., Straburzyńska‐Migaj, E., Bělohlávek, J., Fonseca, C., Mueller, C. E., Lonn, E., Chakrabarti, A., Bao, W., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1670 · Cited by 77
Buono, M. G. D., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R. A., Crea, F., et al. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.011 · Cited by 73
Financial burden, distress, and toxicity in cardiovascular disease
Slavin, S. D., Khera, R., Zafar, S. Y., Nasir, K., & Warraich, H. J. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.04.011 · Cited by 71
Mechanisms and Models in Heart Failure: A Translational Approach
Mann, D. L., & Felker, G. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318158 · Cited by 84
Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery
Boulet, J., & Mehra, M. R. (2021) · Structural Heart · doi:10.1080/24748706.2021.1954275 · Cited by 85
Heart Failure Subtypes and Cardiomyopathies in Women
DeFilippis, E. M., Beale, A., Martyn, T., Agarwal, A., Elkayam, U., Lam, C. S. P., & Hsich, E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319900 · Cited by 77
Cardiovascular Disease in Duchenne Muscular Dystrophy
Schultz, T., Raucci, F. J., & Salloum, F. N. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.11.004 · Cited by 86
“The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrated a 20% reduction in mortality and a reduction in HF admission with sacubitril/valsartan compared with standard treatment with an ACE inhibitor.(123) More recently, clinica…”
ResultJanse, R. J., Fu, E. L., Dahlström, U., Benson, L., Lindholm, B., van Diepen, M., Dekker, F. W., Lund, L. H., Carrero, J. J., & Savarese, G. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2620 · Cited by 79
Mitsas, A. C., Elzawawi, M., Mavrogeni, S. I., Boekels, M., Khan, A. A., Eldawy, M., Stamatakis, I., Kouris, D., Daboul, B., Gunkel, O., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237041 · Cited by 89
“The evidence on the effects of the ARNI sacubitril/valsartan, in addition to its proven benefits for heart failure outcomes, including both CHF and AHF with (HFrEF) [99,100], has shown that ARNI preserve renal function and inhibit the progressive decline of GFR associated with HF more effectively than ACEi and ARB [39…”
BackgroundMascolo, A., Sessa, M., Scavone, C., Angelis, A. D., Vitale, C., Berrino, L., Rossi, F., Rosano, G. M. C., & Capuano, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.069 · Cited by 72
Rufibach, K. (2018) · Pharmaceutical Statistics · doi:10.1002/pst.1917 · Cited by 74
cGMP Signaling and Vascular Smooth Muscle Cell Plasticity
Lehners, M., Dobrowinski, H., Feil, S. C., & Feil, R. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5020020 · Cited by 78
“For example, the PDE5 inhibitor sildenafil is used for erectile dysfunction, the GC-C agonist linaclotide for chronic idiopathic constipation and irritable bowel syndrome, and recently a combination drug consisting of valsartan (an angiotensin II receptor blocker) and sacubitril, which inhibits the ANP-/BNP-degrading…”
BackgroundFu, S., Ping, P., Zhu, Q., Ye, P., & Luo, L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00692 · Cited by 74
“However, considering the presence of BNP in blood and its sensitivity to neprilysin, a relatively modest increase in plasma BNP levels may also account for improved prognosis with LCZ696 in patients with HF (McMurray et al., 2014).”
BackgroundTargeting Calpain for Heart Failure Therapy
Wang, Y., Chen, B., Huang, C.-K., Guo, A., Wu, J. D., Zhang, X., Chen, R., Chen, C., Kutschke, W. J., Weiss, R. M., et al. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.05.004 · Cited by 67
“A recent PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial demonstrated superior cardiovascular mortality benefit by combining an angiotensin receptor inhibitor with an inhibitor of neprilysin, a neutral endopeptidase that degrades vasoa…”
BackgroundMethodTan, N. Y. L., Sangaralingham, L. R., Sangaralingham, S. J., Yao, X., Shah, N. D., & Dunlay, S. M. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.003 · Cited by 74
“We were surprised by this given the large reduction in HF hospitalization risk with sacubitril-valsartan in PARADIGM-HF.”
BackgroundResultInfluentialPrioritizing symptom management in the treatment of chronic heart failure
Koshy, A. O., Gallivan, E. R., McGinlay, M., Straw, S., Drozd, M., Toms, A. G., Gierula, J., Cubbon, R. M., Kearney, M. T., & Witte, K. K. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12875 · Cited by 66
Suzuki, K., Claggett, B. L., Minamisawa, M., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Lefkowitz, M. P., Shi, V. C., McMurray, J. J. V., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1853 · Cited by 74
Self-citationTeerlink, J. R., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I. S., Arias‐Mendoza, A., Biering‐Sørensen, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2015 · Cited by 68
Self-citationSex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes
Sullivan, K., Doumouras, B. S., Santema, B. T., Walsh, M. N., Douglas, P. S., Voors, A. A., & Spall, H. G. C. V. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.025 · Cited by 72
Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
Bhatt, A. S., Varshney, A. S., Moscone, A., Claggett, B. L., Miao, Z. M., Chatur, S., Lopes, M. S., Ostrominski, J. W., Pabón, M. A., Ünlü, O., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.029 · Cited by 73
Self-citationInnovation in Heart Failure Treatment
Nuys, K. E. V., Xie, Z., Tysinger, B., Hlatky, M. A., & Goldman, D. P. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.12.006 · Cited by 73
Huo, Y., Li, W., Webb, R. L., Zhao, L., Wang, Q., & Guo, W. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13437 · Cited by 75
Chronic kidney disease, heart failure and neprilysin inhibition
Haynes, R., Zhu, D., Judge, P. K., Herrington, W. G., Kalra, P. A., & Baigent, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz058 · Cited by 70
“Sacubitril/valsartan is now recommended in the European Society of Cardiology guidelines as a replacement for ACEi (or ARB) in patients who have symptomatic HF with a reduced LVEF 35% and who remain symptomatic despite maximumtolerated evidence-based treatment [29, 40].”
BackgroundDoes the heart transplant have a future?
Fuchs, M., Schibilsky, D., Zeh, W., Berchtold‐Herz, M., Beyersdorf, F., & Siepe, M. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz107 · Cited by 74
“Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18].”
BackgroundPerego, C., Sbolli, M., Specchia, C., Fiuzat, M., McCaw, Z. R., Metra, M., Oriecuia, C., Peveri, G., Wei, L., O’Connor, C. M., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.07.005 · Cited by 76
Stem cell therapy in the heart: Biomaterials as a key route
Hashemzadeh, M. R., Yazdi, M. E. T., Amiri, M. S., & Mousavi, S. H. (2021) · Tissue and Cell · doi:10.1016/j.tice.2021.101504 · Cited by 70
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi, K. F., Dayoub, E. J., Ross, J. S., Dhruva, S. S., Ahmad, T., & Desai, N. R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.031 · Cited by 69
Emerging molecular imaging targets and tools for myocardial fibrosis detection
Barton, A. K., Tzolos, E., Bing, R., Singh, T., Weber, W., Schwaiger, M., Varasteh, Z., Slart, R. H. J. A., Newby, D. E., & Dweck, M. R. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac242 · Cited by 68
“Development of anti-fibrotic therapies Our previous inability to measure fibrosis activity means that we do not fully understand the anti-fibrotic effects of routinely used heart failure medications even though they improve cardiovascular outcomes in large randomized controlled trials.(83,84) Heart failure therapies g…”
BackgroundRole of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease
Frąk, W., Dąbek, B., Balcerczyk-Lis, M., Motor, J., Radzioch, E., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Antioxidants · doi:10.3390/antiox13060687 · Cited by 86
“Moreover, they antagonize the actions of the RAAS, thereby counteracting vasoconstriction, sodium retention, and fibrosis in the kidneys [115,116].”
BackgroundGreene, S. J., Fonarow, G. C., Solomon, S. D., Subacius, H. P., Maggioni, A. P., Böhm, M., Lewis, E. F., Zannad, F. M., Gheorghiade, M., & for the ASTRONAUT Investigators and Coordinators (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.280 · Cited by 67
Self-citationUsing Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
Kithcart, A. P., & MacRae, C. A. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.01.004 · Cited by 77
“Similarly, the knowledge that heart failure is caused by mutations in cardiomyocyte structural proteins has not led to a single new agent’s entering the market, though there have been several notable serendipitous successes during this period, including mineralocorticoid receptor antagonists and neprilysin inhibitors…”
BackgroundThe Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 79
Dewan, P., Jhund, P. S., Shen, L., Petrie, M. C., Abraham, W. T., Ali, M. A., Chen, C., Desai, A. S., Dickstein, K., Huang, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1347 · Cited by 65
Self-citationPacker, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Self-citationHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Jhund, P. S., Ponikowski, P., Docherty, K. F., Gasparyan, S. B., Böhm, M., Chiang, C.-E., Desai, A. S., Howlett, J., Kitakaze, M., Petrie, M. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053659 · Cited by 64
Self-citationSacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
Niu, C., Yang, S., Ou, S., Wu, C., Huang, P., Hung, C., Lin, C., & Li, S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026407 · Cited by 70
Shah, A. M., Claggett, B. L., Prasad, N., Li, G., Volquez, M., Jering, K., Čikeš, M., Kovács, A. D., Müllens, W., Nicolau, J. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059210 · Cited by 73
Self-citationEpidemiology of heart failure in diabetes: a disease in disguise
Hoek, A. G., Canto, E. D., Wenker, E., Bindraban, N. R., Handoko, M. L., Elders, P. J. M., & Beulens, J. W. J. (2024) · Diabetologia · doi:10.1007/s00125-023-06068-2 · Cited by 80
Novel Interventional Therapies to Modulate the Autonomic Tone in Heart Failure
Chatterjee, N. A., & Singh, J. P. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.05.008 · Cited by 67
“In the face of rising HF morbidity, mortality, and costs, there have been important contemporary advances in both pharmacological (5) and nonpharmacological therapies (6), although their application and benefit are often restricted to a subset of patients (7).”
BackgroundCoQ10Function and Role in Heart Failure and Ischemic Heart Disease
Ayer, A., Macdonald, P., & Stocker, R. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034258 · Cited by 64
Developing New Treatments for Heart Failure: Focus on the Heart
Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P., Epstein, S. E., Kim, R. J., Parsey, R. V., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002727 · Cited by 64
“successful phase III clinical trials with this population during the past decade have been rare.(1,3,4) Moreover, and perhaps”
BackgroundMethodLow- and High-renin Heart Failure Phenotypes with Clinical Implications
Pávó, N., Goliasch, G., Wurm, R., Novak, J. F., Strunk, G., Gyöngyösi, M., Poglitsch, M., Säemann, M. D., & Hülsmann, M. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.278705 · Cited by 72
Heart Failure in the Outpatient Versus Inpatient Setting: Findings from the BIOSTAT-CHF Study
Ferreira, J. P., Metra, M., Mordi, I. R., Gregson, J., ter Maaten, J. M., Tromp, J., Anker, S. D., Dickstein, K., Hillege, H. L., Ng, L. L., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1323 · Cited by 64
Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in Germany
Wachter, R., Fonseca, A. F., Balas, B., Kap, E. J., Engelhard, J., Schlienger, R. G., Klebs, S. H. G., Wirta, S. B., & Kostev, K. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1465 · Cited by 67
Gál, R., Deres, L., Horváth, O., Erős, K., Sándor, B., Urban, P. P., Soós, S., Márton, Z., Sümegi, B., Tóth, K., et al. (2020) · Antioxidants · doi:10.3390/antiox9111108 · Cited by 67
Blumer, V. L., Greene, S. J., Wu, A., Butler, J., Ezekowitz, J. A., Lindenfeld, J. M., Alhanti, B., Hernandez, A. F., O’Connor, C. M., & Mentz, R. J. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.12.011 · Cited by 66
Current and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 72
Similarities and Differences Between HFmrEF and HFpEF
Li, P., Zhao, H., Zhang, J., Ning, Y., Tu, Y., Xu, D., & Zeng, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678614 · Cited by 75
New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy
Gallo, G., Lanza, O., & Savoia, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065089 · Cited by 84
Current concepts in coronary artery revascularisation
Gaudino, M. F. L., Andreotti, F., & Kimura, T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00459-2 · Cited by 81
Malgie, J., Clephas, P. R. D., Rocca, H. B., de Boer, R. A., & Brugts, J. J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10325-2 · Cited by 86
“For example, the use of ARNi is discouraged in patients with eGFR < 30 simply because such patients have been excluded from the according trial [4, 16].”
BackgroundRecent successes in heart failure treatment
Lam, C. S. P., Docherty, K. F., Ho, J. E., McMurray, J. J. V., Myhre, P. L., & Omland, T. (2023) · Nature Medicine · doi:10.1038/s41591-023-02567-2 · Cited by 71
“Sacubitril/valsartan is a first-in-class ARNI, which was compared with the gold-standard angiotensin-converting enzyme (ACE) inhibitor enalapril in patients with ambulatory HFrEF in the PARADIGM-HF trial 23 .”
Self-citationNdumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Cyclic Nucleotide Signalling in Kidney Fibrosis
Schinner, E., Wetzl, V., & Schlossmann, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022320 · Cited by 69
“with reduced ejection fraction as they are superior to angiotensin-converting enzyme (ACE) inhibition by reducing risk of death and hospitalization in heart failure [176].”
Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G
Rainer, P. P., & Kass, D. A. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw107 · Cited by 65
Wang, J., Yukisada, K., Sibulo, A. S., Hafeez, K., Jia, Y., & Zhang, J. Y. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001219 · Cited by 63
Predictive model identifies key network regulators of cardiomyocyte mechano-signaling
Tan, P. M., Buchholz, K. S., Omens, J. H., McCulloch, A. D., & Saucerman, J. J. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005854 · Cited by 66
Wolsk, E., Claggett, B. L., Køber, L., Pocock, S., Yusuf, S., Swedberg, K. B., McMurray, J. J. V., Granger, C. B., Pfeffer, M. A., & Solomon, S. D. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1073 · Cited by 67
Self-citationPfau, D. J., Thorn, S., Zhang, J., Mikush, N., Renaud, J. M., Klein, R., deKemp, R. A., Wu, X., Hu, X., Sinusas, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42113-0 · Cited by 63
Sacubitril/valsartan for heart failure in adults with complex congenital heart disease
Maurer, S. J., Pujol, C., Schiele, S., Hager, A., Ewert, P., & Tutarel, O. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.031 · Cited by 63
Serum Potassium in the PARADIGM-HF Trial
Ferreira, J. P., Mogensen, U. M., Jhund, P. S., Desai, A. S., Rouleau, J. L., Zile, M. R., Rossignol, P., Zannad, F. M., Packer, M., Solomon, S. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1987 · Cited by 64
Self-citationIntracrine angiotensin II functions originate from noncanonical pathways in the human heart
Ferrario, C. M., Ahmad, S., Varagić, J., Cheng, C. P., Groban, L., Wang, H., Collawn, J. F., & Dell’Italia, L. J. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00219.2016 · Cited by 67
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000099 · Cited by 70
Martin, N., Manoharan, K., Davies, C., & Lumbers, R. T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721.pub3 · Cited by 85
Sex-Based Differences in Heart Failure
Khan, S. S., Beach, L. B., & Yancy, C. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.013 · Cited by 73
Senni, M., López-Sendón, J., Solal, A. C., Ponikowski, P. P., Nkulikiyinka, R., Freitas, C., Vlajnic, V., Roessig, L., & Pieske, B. M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14050 · Cited by 65
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 76
Orsborne, C., Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134045 · Cited by 79
Heart Failure with Reduced Ejection Fraction in Women
Mentzer, G. G., & Hsich, E. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.08.003 · Cited by 71
Emerging Drug Classes and Their Potential Use in Hypertension
Azizi, M., Rossignol, P., & Hulot, J. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12676 · Cited by 69
Görenek, B., Halvorsen, S., Kudaiberdieva, G., Bueno, H., Gelder, I. C. V., Lettino, M., Marín, F. R., Masip, J., Mueller, C. E., Okutucu, S., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872619894255 · Cited by 79
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Insights Into Implementation of Sacubitril/Valsartan Into Clinical Practice
Martens, P., Beliën, H., Dupont, M., & Müllens, W. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12258 · Cited by 68
“For instance, the drop in systolic blood pressure was more pronounced in our patient population in comparison with that seen in PARADIGM-HF.(1,3) Nevertheless, it is of upmost importance to emphasize that this does not mean that these patients benefit less from a switch of their ACE-I or ARB to sacubitril/valsartan.”
BackgroundMethodResultInfluentialUse of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
Gregorietti, V., López‐Fernández, T., Costa, D., Chahla, E. J. O., & Daniele, A. J. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-00078-4 · Cited by 61
Bass-Stringer, S., Tai, C. M. K., & McMullen, J. R. (2020) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2020.11.009 · Cited by 72
“Moreover, combined therapeutic approaches to treat cardiovascular diseases are more frequently being utilized and are showing encouraging outcomes in recent times.(43,44) Approaches our laboratory are investigating include PI3K therapies that utilize adeno-associated virus (AAV) gene therapy, as well as the identifica…”
BackgroundDeFilippis, E. M., Echols, M. R., Adamson, P. B., Batchelor, W., Cooper, L. B., Cooper, L. S., Desvigne-Nickens, P. M., George, R. T., Ibrahim, N. E., Jessup, M. L., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0161 · Cited by 61
Making Sense of Composite Endpoints in Clinical Research
Baracaldo-Santamaría, D., Feliciano-Alfonso, J. E., Grueso, R. R., Rojas-Rodríguez, L. C., Domínguez-Domínguez, C. A., & Calderón‐Ospina, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134371 · Cited by 74
“PARADIGM-HF trial Death from cardiovascular causes or a first hospitalization for heart failure Treatment with sacubitril–valsartan versus enalapril in patients with heart failure significantly reduced the rate of the composite outcome -Served as the basis to justify the regulatory approval and the clinical use of sac…”
BackgroundMogensen, U. M., Køber, L., Jhund, P. S., Desai, A. S., Senni, M., Kristensen, S. L., Dukát, A., Chen, C., Ramires, F. J. A., Lefkowitz, M. P., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1056 · Cited by 65
Self-citationBlood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk
Bergmark, B. A., Scirica, B. M., Steg, P. G., Fanola, C. L., Gurmu, Y., Mosenzon, O., Cahn, A., Raz, I., Bhatt, D. L., & SAVOR-TIMI 53 Investigators (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx809 · Cited by 61
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.